Asklepios BioPharmaceutical
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders.
About Asklepios BioPharmaceutical
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders and other rare diseases. It offers proprietary AAV technology, manufacturing capabilities, and a robust pipeline of in-house clinical programs for clients in the medical biopharmaceutical industry. Its pipeline includes clinical-stage programs in Pompe disease and congestive heart failure and a diverse preclinical portfolio of therapeutics targeting neuromuscular, CNS, and other diseases, as well as out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. The company’s gene therapy platform includes Pro10, an industry-leading proprietary cell line manufacturing process, and an extensive AAV capsid, and promoter library. Asklepios BioPharmaceutical was founded in 2001 and is headquartered in Research Triangle Park, North Carolina.
Company Facts
- Headquarters
- Chapel Hill
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00501_01000
- Funding Stage
- m_and_a
- Total Funding
- $241,756,252
- Last Funding Type
- grant
- Last Funding Date
- 2020-09-02
- Website
- askbio.com
Industries & Categories
Biopharma, Biotechnology, Health Care, Manufacturing, Medical, Medical Device
Social Links
Canonical: https://fsome.com/organization/asklepios-biopharmaceutical-32322 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.